Judith A Gilbert. Show Affiliations »
Abstract
Entities: Chemical Disease Gene
Mesh： See more » Anaplastic Lymphoma KinaseAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useBiomarkers, Tumor/antagonists & inhibitorsBiomarkers, Tumor/metabolismCarbazoles/adverse effectsCarbazoles/therapeutic useCarcinoma, Non-Small-Cell Lung/drug therapyCarcinoma, Non-Small-Cell Lung/enzymologyCarcinoma, Non-Small-Cell Lung/mortalityClinical Trials, Phase III as TopicCrizotinibDisease-Free SurvivalHumansLung Neoplasms/drug therapyLung Neoplasms/enzymologyLung Neoplasms/mortalityPiperidines/adverse effectsPiperidines/therapeutic useProtein Kinase Inhibitors/adverse effectsProtein Kinase Inhibitors/therapeutic usePyrazoles/adverse effectsPyrazoles/therapeutic usePyridines/adverse effectsPyridines/therapeutic useRandomized Controlled Trials as TopicReceptor Protein-Tyrosine Kinases/antagonists & inhibitorsReceptor Protein-Tyrosine Kinases/metabolismTreatment Outcome
Substances： See more » Antineoplastic AgentsBiomarkers, TumorCarbazolesPiperidinesProtein Kinase InhibitorsPyrazolesPyridinesCrizotinibALK protein, humanAnaplastic Lymphoma KinaseReceptor Protein-Tyrosine Kinasesalectinib
Year: 2017 PMID： 28625556 DOI： 10.1016/S1470-2045(17)30482-5
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316